Jonah Feldman is an assistant editor for Targeted Oncology and Peers and Perspectives in Oncology.
Nivolumab Plus Ipilimumab Prolongs Survival in Mesothelioma
In an interview with Targeted Oncology, Solange Peters, MD, discussed the significance of the 3-year follow-up analysis of the CheckMate 743 study of nivolumab/ipilimumab in mesothelioma.
Apalutamide Linked with Lower Risk of Death in Prostate Cancer
Neeraj Agarwal, MD, spoke with Targeted Oncology about the success of the TITAN and SPARTAN studies as well as its use in real-world prostate cancer populations.
Rebastinib/Paclitaxel Shows Efficacy in Platinum-Resistant Ovarian Cancer
In an interview with Targeted Oncology, Erika Hamilton, MD, discussed the findings from a study of rebastinib plus paclitaxel and unmet needs in the ovarian cancer setting.